Hence, we reasoned that co-inhibition of BCL2 and MCL1 in nf1/pten-mutant melanoma cells might produce an even greater synergistic antitumor effect than observed with either inhibitor given individually with sirolimus. The gene discussed is MCL1; the disease is melanoma.